J. Brewer

发表

The HLA A*0201–restricted hTERT540–548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor

J. E. Brewer, A. Sewell, M. Purbhoo, 2007, Molecular Cancer Therapeutics.

Receptors Tumor Cells Using High Affinity T Cell NY-ESO-1 / LAGE-1-Derived Epitopes on Quantifying and Imaging

J. E. Brewer, P. Vyas, J. Karbach, 2006 .

CLINICAL Cardiovascular toxicity and titin cross-reactivity of af ﬁ nity-enhanced T cells in myeloma and melanoma

G. Linette, A. Bagg, B. Levine, 2013 .

HPLC and flow cytometric analyses of uptake of adriamycin and menogaril by monolayers and multicell spheroids.

E. G. Adams, W. Adams, B. Bhuyan, 1990, Selective cancer therapeutics.

Determination of glyburide in human serum by liquid chromatography with fluorescence detection.

W. Adams, M. Courtney, J. Brewer, 1982, Analytical chemistry.

An Isocratic Liquid Chromatographic Method with Diode-Array Detection for the Simultaneous Determination of -Tocopherol, Retinol, and Five Carotenoids in Human Serum

Phyllis R. Brown, Kiyokatsu Jinno, Roman Kaliszan, 2002 .

Reversed-Liquid Phase Chromatographic Determination of Cefpodoxime in Human Plasma

R. Steenwyk, M. Royer, J. Brewer, 1991 .

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Adam Bagg, Marcela V Maus, Bent K Jakobsen, 2013, Blood.

High-affinity small molecule inhibitors of T cell costimulation: compounds for immunotherapy.

J. E. Brewer, P. Huxley, Daniel D Williams, 2004, Chemistry & biology.

NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

J. E. Brewer, B. Levine, M. Kalos, 2015, Nature Medicine.

Human leucocyte antigen class I‐redirected anti‐tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells

J. E. Brewer, A. Sewell, B. Jakobsen, 2016, Clinical and experimental immunology.

T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells

J. E. Brewer, A. Sewell, B. Jakobsen, 2015, Clinical and experimental immunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Bent K Jakobsen, J. E. Brewer, Gabriela Plesa, 2013, Science Translational Medicine.

Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors

Bent K Jakobsen, J. E. Brewer, Marco A Purbhoo, 2006, The Journal of Immunology.

Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β

J. E. Brewer, A. Rust, B. Jakobsen, 2021, The Journal of Immunology.

High affinity soluble ILT2 receptor: a potent inhibitor of CD8+ T cell activation

J. E. Brewer, B. Jakobsen, R. Ashfield, 2010, Protein & Cell.

Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.

J. E. Brewer, E. Dalm, W. Adams, 1989, Cancer research.

Protein binding of tirilazad (U-74006) in human, Sprague-Dawley rat, beagle dog and cynomolgus monkey serum.

J. E. Brewer, M. G. Johnson, J. Brewer, 1994, The Journal of pharmacology and experimental therapeutics.